The scrip opened at Rs. 1580.00 and has touched a high and low of Rs. 1648.00 and Rs. 1554.65 respectively. So far 44807 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 5 has touched a 52 week high of Rs. 1,964.00 on 29-Mar-2019 and a 52 week low of Rs. 1453.00 on 23-Jul-2019.
Last one week high and low of the scrip stood at Rs. 1670.35 and Rs. 1554.65 respectively. The current market cap of the company is Rs. 27513.34 crore.
The promoters holding in the company stood at 71.25%, while Institutions and Non-Institutions held 18.80% and 9.95% respectively.
Torrent Pharmaceuticals has received a warning letter from the US Food and Drug Administration (USFDA) for its Indrad facility in Gujarat. This action by the USFDA follows earlier intimation received from the regulator in August 2019, wherein the agency had classified its inspection as ‘Official Action Indicated’ (OAI). The company is committed in maintaining the highest standards of compliances and quality manufacturing across all its facilities.
Torrent Pharmaceuticals is Flagship Company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.
